Another GWAX done in 20197 expanded its sample size by meta–analysing the IGAP stage 1 discovery sample,5 a new GWAS from the Psychiatric Genomics Consortium (n=17 477), exome–wide data from the Alzheimer’s Disease Sequencing Project (n=7506), and a GWAX from the UK Biobank (71 880 proxy cases and 383 378 proxy controls) for a total sample of 534 403 individuals. Sample overlap between the Alzheimer’s Disease Sequencing Project and IGAP was accounted for statistically. Instead of meta-analysing paternal and maternal cases and controls, this GWAX used the number of parents with Alzheimer’s disease weighted by the probability of being a case or control on the basis of parental age, rather than excluding participants. This analysis identified 29 susceptibility loci.
